Multi-stent delivery system

• US 8,012,192 B2
• Filed: 02/18/2004
• Issued: 09/06/2011
• Est. Priority Date: 02/18/2004
• Status: Active Grant

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Inventors: Gregorich, Daniel, Weber, Jan, Eidenschink, Tracee
• Primary Examiner(s): Bui; Vy Q
• Application Number:
  US10/780,937
• Publication Number:
  US 20050182473A1
• Time in Patent Office: 2,757 Days
• Field of Search: 623/1.11, 623/1.12, 623/1.13, 623/1.23, 623/1.35, 606/108, 606/198, 606/194, 606/195, 604/96.01, 604/103.03, 604/171
• US Class Current: 623/1.11
• CPC Class Codes: A61F 2/852 Two or more distinct overlapping stents
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2/954 for placing stents or stent-grafts in a bifurcation
• CPC Class Codes: A61F 2/958 Inflatable balloons for placing stents or stent-grafts
• CPC Class Codes: A61F 2002/826 more than one stent being applied sequentially
• CPC Class Codes: A61F 2250/0039 differing in diameter
• CPC Class Codes: A61F 2250/006 modular
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence

Abstract

A catheter assembly comprises a catheter having a catheter shaft with a first rotatable sheath rotatably disposed thereabout. A first guidewire housing which defines a first guidewire lumen for passage of a first guidewire therethrough is engaged to the first rotatable sheath. A first stent, which when in the reduced stent state, is disposed about at least a portion of the first rotatable sheath. A second stent, which when in the reduced stent state, is positioned adjacent to the first stent.

Claims

1. A catheter assembly comprising:

a catheter, the catheter comprising a catheter shaft;

a first rotatable sheath, the first rotatable sheath including a radial outer surface and a radial inner surface, the first rotatable sheath being disposed about and rotatable relative to a portion of the catheter shaft, the first rotatable sheath having a length substantially less than that of the catheter shaft, the first rotatable sheath being expandable from a reduced sheath state to an expanded sheath state, in the reduced sheath state the first sheath being rotatable about the portion of the catheter shaft;

a first guidewire housing, the first guidewire housing defining a first guidewire lumen for passage of a first guidewire therethrough, at least a portion of the first guidewire housing being engaged to the radial outer surface of the first rotatable sheath;

a first stent, the first stent being expandable from a reduced stent state to an expanded stent state, in the reduced stent state the stent being disposed about at least a portion of the first rotatable sheath and at least a portion of the first guidewire housing; and

a second stent, the second stent being expandable from a reduced stent state to an expanded stent state, in the reduced stent state the second stent being disposed about the catheter shaft adjacent to the first stent.

2. The catheter assembly of claim 1 wherein the portion of the catheter shaft comprises a balloon.

3. The catheter assembly of claim 2 wherein when the second stent is in the reduced stent state the second stent is disposed about the catheter shaft longitudinally adjacent to the first rotatable sheath.

4. The catheter assembly of claim 2 wherein when the second stent is in the reduced stent state the second stent is positioned longitudinally adjacent to the first stent along the first rotatable sheath.

5. The catheter assembly of claim 1 wherein when the second stent is in the reduced stent state the second stent is disposed about the catheter shaft longitudinally adjacent to the first rotatable sheath.

6. The catheter assembly of claim 1 wherein when the second stent is in the reduced stent state the second stent is positioned longitudinally adjacent to the first stent along the first rotatable sheath.

7. The catheter assembly of claim 1 wherein when the first stent is in the reduced stent state at least a portion of the first stent overlays at least a portion of the first guidewire housing.

8. The catheter assembly of claim 7 wherein when the first stent is in the reduced stent state at least a distal portion of the first guidewire housing extends externally from the fist stent to a position between the first stent and the second stent.

9. The catheter assembly of claim 8 wherein the second stent comprises a distal end region, a proximal end region and a body region therebetween, in the reduced stent state at least the proximal end region having a diameter less than that of the body region.

10. The catheter assembly of claim 8 wherein the diameter of at least the proximal end region tapers from the body region.

11. The catheter assembly of claim 1 further comprising a second rotatable sheath, the second rotatable sheath being disposed about a portion of the catheter shaft longitudinally adjacent the first rotatable sheath, the second rotatable sheath being expandable from a reduced sheath state to an expanded sheath state, in the reduced sheath state the second sheath being rotatable about the portion of the catheter shaft longitudinally adjacent the first rotatable sheath, the second rotatable sheath having a length substantially less than that of the catheter shaft;

and

a second guidewire housing, the second guidewire housing defining a second guidewire lumen for passage of a second guidewire therethrough, at least a portion of the second guidewire housing being engaged to the second rotatable sheath.

12. The catheter assembly of claim 11 wherein the portion of the catheter shaft comprises a first balloon and the portion of the catheter longitudinally adjacent the first rotatable sheath comprises a second balloon.

13. The catheter assembly of claim 1 further comprising a second rotatable sheath, when the first stent is in the reduced stent state the second rotatable sheath is rotatably disposed about at least a portion of the first stent, in the reduced stent state the second stent is disposed about the second rotatable sheath.

14. The catheter assembly of claim 13 wherein the second rotatable sheath is bio-absorbable.

15. The catheter assembly of claim 13 wherein the second rotatable sheath is retractable from about the first stent.

16. The catheter assembly of claim 13 wherein the second rotatable sheath is expandable from a reduced sheath state to an expanded sheath state.

17. The catheter assembly of claim 13 wherein at least a portion of at least one member of the group consisting of the first stent, the second stent, the first rotatable sheath, the second rotatable sheath, and any combination thereof is coated with at least one therapeutic agent.

18. The catheter assembly of claim 1 wherein the first stent is selected from at least one member of the group consisting of:

a self-expanding stent, a balloon-expandable stent, a hybrid expandable stent and any combination thereof.

19. The catheter assembly of claim 1 wherein the second stent is selected from at least one member of the group consisting of:

a self-expanding stent, a balloon-expandable stent, a hybrid expandable stent and any combination thereof.

20. The catheter assembly of claim 1 wherein at least a portion of at least one member of the group consisting of the first stent, the second stent, the first rotatable sheath and any combination thereof is coated with at least one therapeutic agent.

21. The catheter assembly of claim 20 wherein the at least one therapeutic agent is at least one non-genetic therapeutic agent selected from at least one member of the group consisting of anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone);

anti-proliferative agents such as enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid;

anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine;

antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors;

anesthetic agents such as lidocaine, bupivacaine and ropivacaine;

anti-coagulants such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;

vascular cell growth promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters, vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin;

bifunctional molecules consisting of an antibody and a cytotoxin;

cholesterol-lowering agents;

vasodilating agents; and

agents which interfere with endogenous vascoactive mechanisms, and any combinations thereof.

22. The catheter assembly of claim 20 wherein the at least one therapeutic agent is at least one genetic therapeutic agent selected from at least one member of the group consisting of:

anti-sense DNA and RNA;

DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules;

angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor .alpha. and .beta., platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor and insulin like growth factor;

cell cycle inhibitors including CD inhibitors, thymidine kinase (“

TK”

) and other agents useful for interfering with cell proliferation;

at least one of the family of bone morphogenic proteins (“

BMP'"'"'s”

) such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7;

dimeric proteins such as homodimers, heterodimers, or combinations thereof, alone or together with other molecules;

molecules capable of inducing an upstream or downstream effect of a BMP such as “

hedgehog”

proteins, or the DNA'"'"'s encoding them and any combinations thereof.

23. The catheter assembly of claim 20 wherein the at least one therapeutic agent is at least one type of cellular material selected from at least one member of the group consisting of:

cells of human origin (autologous or allogeneic);

cells of non-human origin (xenogeneic) and any combination thereof.

24. The catheter assembly of claim 23 wherein the cellular material is selected from at least one member of the group consisting of:

side population cells;

lineage negative cells;

lineage negative CD34⁻

cells;

lineage negative CD34⁺ cells;

lineage negative⁻

cKit⁺ cells;

mesenchymal stem cells;

cord blood bells;

cardiac or other tissue derived stem cells;

whole bone marrow;

bone marrow mononuclear cells;

endothelial progenitor cells;

satellite cells;

muscle derived cells;

go cells;

endothelial cells;

adult cardiomyocytes;

fibroblasts;

smooth muscle cells;

cultures of mesenchymal stem cells with 5-aza forces differentiation into cardiomyocytes;

adult cardiac fibroblasts+5-aza;

genetically modified cells;

tissue engineered grafts;

MyoD scar fibroblasts;

Pacing cells;

embryonic stem cell clones;

embryonic stem cells;

fetal or neonatal cells;

immunologically masked cells;

tissue engineered grafts;

genetically modified cells;

teratoma derived cells and any combinations thereof.

25. The catheter assembly of claim 20 wherein the at least one therapeutic agent comprises at least one polymer coating, the at least one coating selected from at least one member of the group consisting of:

polycarboxylic acids;

cellulosic polymers, including cellulose acetate and cellulose nitrate;

gelatin;

polyvinylpyrrolidone;

cross-linked polyvinylpyrrolidone;

polyanhydrides including maleic anhydride polymers;

polyamides;

polyvinyl alcohols;

copolymers of vinyl monomers such as EVA;

polyvinyl ethers;

polyvinyl aromatics;

polyethylene oxides;

glycosaminoglycans;

polysaccharides;

polyesters including polyethylene terephthalate;

polyacrylamides;

polyethers;

polyether sulfone;

polycarbonate;

polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene;

halogenated polyalkylenes including polytetrafluoroethylene;

polyurethanes;

polyorthoesters;

proteins;

polypeptides;

silicones;

siloxane polymers;

polylactic acid;

polyglycolic acid;

polycaprolactone;

polyhydroxybutyrate valerate and blends and copolymers thereof;

coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®

, etc.), fibrin, collagen and derivatives thereof;

polysaccharides such as celluloses, starches, dextrans, alginates and derivatives;

hyaluronic acid;

squalene emulsions;

polyacrylic acid, a copolymer of polylactic acid and polycaprolactone;

medical-grade biodegradable materials such as PGA-TMC, Tyrosine-Derived Polycarbonates and arylates;

polycaprolactone co butyl acrylate and other co polymers;

Poly-L-lactic acid blends with DL-Lactic Acid;

Poly(lactic acid-co-glycolic acid);

polycaprolactone co PLA;

polycaprolactone co butyl acrylate and other copolymers;

Tyrosine-Derived Polycarbonates and arylate;

poly amino acid;

polyphosphazenes;

polyiminocarbonates;

polydimethyltrimethylcarbonates;

biodegradable CA/PO₄ '"'"'s;

cyanoacrylate;

50/50 DLPLG;

polydioxanone;

polypropylene fumarate;

polydepsipeptides;

macromolecules such as chitosan and Hydroxylpropylmethylcellulose;

surface erodible material;

maleic anhydride copolymers;

zinc-calcium phosphate;

amorphous polyanhydrides;

sugar;

carbohydrate;

gelatin;

biodegradable polymers; and

polymers dissolvable in bodily fluids;

A block copolymers;

B block copolymers and any combinations thereof.

26. The catheter assembly of claim 1 further comprising a lubricious coating, the lubricious coating positioned between at least a portion of the first rotatable sheath and the a portion of the catheter shaft.

27. The catheter assembly of claim 1 wherein the first rotatable sheath is at least partially constructed from a hydrophilic polymer material.

28. The catheter assembly of claim 1 wherein the first rotatable sheath is at least partially constructed from a tecophilic material.

29. The catheter assembly of claim 1 wherein the first rotatable sheath is at least partially constructed from a first material and a second material.

30. The catheter assembly of claim 29 wherein the first material is a polymer matrix and the second material is at least one distinct member of reinforcing material at least partially supported within the polymer matrix.

31. The catheter assembly of claim 30 wherein polymer matrix is selected from at least one material from the group consisting of:

hydrophilic polyurethanes, aromatic polyurethanes, polycarbonate base aliphatic polyurethanes, engineering polyurethane, elastomeric polyamides, block polyamide/ethers, polyether block amide, silicones, polyether-ester, polyester, polyester elastomer, polyethylene and any combination thereof.

32. The catheter assembly of claim 30 wherein the reinforcing material is selected from at least one material of the group consisting of polyamide, polyethylene, high-density polyethylene, polyetheretherketone, polyimide, polyetherimide, liquid crystal polymers, acetal, and any combination thereof.

33. The catheter assembly of claim 1 wherein the first rotatable sheath is at least partially constructed from at least one material of the group consisting of:

hydrophilic polyurethanes, aromatic polyurethanes, polycarbonate base aliphatic polyurethanes, engineering polyurethane, elastomeric polyamides, block polyamide/ethers, polyether block amide, silicones, polyether-ester, polyester, polyester elastomer, polyethylene, polyimide, high-density polyethylene, polyetheretherketone, polyimide, polyetherimide, liquid crystal polymers, acetal, and any combination thereof.